EA200300708A1 - Способы получения мультимерных белков и относящиеся к ним композиции - Google Patents

Способы получения мультимерных белков и относящиеся к ним композиции

Info

Publication number
EA200300708A1
EA200300708A1 EA200300708A EA200300708A EA200300708A1 EA 200300708 A1 EA200300708 A1 EA 200300708A1 EA 200300708 A EA200300708 A EA 200300708A EA 200300708 A EA200300708 A EA 200300708A EA 200300708 A1 EA200300708 A1 EA 200300708A1
Authority
EA
Eurasian Patent Office
Prior art keywords
proteins
multimensive
methods
obtaining
related compositions
Prior art date
Application number
EA200300708A
Other languages
English (en)
Other versions
EA009181B1 (ru
Inventor
Гейс Ван Роэйен
Харм Декерз
Бипин Кумар Далмиа
Грегг Дель Вал
Стив Заплачински
Морис Молони
Original Assignee
Сембайосиз Джинетикс Инк.
Синджента Партисипейшнс Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сембайосиз Джинетикс Инк., Синджента Партисипейшнс Аг filed Critical Сембайосиз Джинетикс Инк.
Publication of EA200300708A1 publication Critical patent/EA200300708A1/ru
Publication of EA009181B1 publication Critical patent/EA009181B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon
    • C12N15/8258—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon for the production of oral vaccines (antigens) or immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8241—Phenotypically and genetically modified plants via recombinant DNA technology
    • C12N15/8242—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits
    • C12N15/8257—Phenotypically and genetically modified plants via recombinant DNA technology with non-agronomic quality (output) traits, e.g. for industrial processing; Value added, non-agronomic traits for the production of primary gene products, e.g. pharmaceutical products, interferon

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)

Abstract

Описаны улучшенные способы получения мультимерных белковых комплексов, таких как редокс-белки и иммуноглобулины, связанных с масляными тельцами. Редокс-белок является ферментативно активным при получении в связанном с масляными тельцами виде. Представлены также имеющие к ним отношение нуклеиновые кислоты, белки, клетки, растения и композиции.Международная заявка была опубликована вместе с отчетом о международном поиске.
EA200300708A 2000-12-19 2001-12-19 Рекомбинантные мультимерные белковые комплексы, связанные с масляными тельцами, способы получения указанных комплексов и масляных телец и содержащие их продукты и композиции EA009181B1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US74290000A 2000-12-19 2000-12-19
US30288501P 2001-07-05 2001-07-05
US603801A 2001-12-04 2001-12-04
PCT/US2001/050240 WO2002050289A1 (en) 2000-12-19 2001-12-19 Methods for the production of multimeric proteins, and related compositions

Publications (2)

Publication Number Publication Date
EA200300708A1 true EA200300708A1 (ru) 2003-12-25
EA009181B1 EA009181B1 (ru) 2007-12-28

Family

ID=27358025

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200300708A EA009181B1 (ru) 2000-12-19 2001-12-19 Рекомбинантные мультимерные белковые комплексы, связанные с масляными тельцами, способы получения указанных комплексов и масляных телец и содержащие их продукты и композиции

Country Status (15)

Country Link
US (1) US20090197337A1 (ru)
EP (1) EP1346056A1 (ru)
JP (1) JP4570327B2 (ru)
KR (1) KR20030066732A (ru)
CN (1) CN100385005C (ru)
AR (1) AR037083A1 (ru)
AU (2) AU3281902A (ru)
BR (1) BR0116220A (ru)
CA (1) CA2432315A1 (ru)
EA (1) EA009181B1 (ru)
IL (1) IL156334A0 (ru)
MX (1) MXPA03005548A (ru)
NZ (1) NZ526822A (ru)
TW (1) TWI317736B (ru)
WO (1) WO2002050289A1 (ru)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7009087B1 (en) 2000-12-01 2006-03-07 Pioneer Hi-Bred International, Inc. Compositions and methods for altering the disulfide status of proteins
US7071307B2 (en) * 2001-05-04 2006-07-04 Syngenta Participations Ag Nucleic acids and proteins with thioredoxin reductase activity
US20060179514A1 (en) * 2001-07-05 2006-08-10 Sembiosys Genetics, Inc. Methods for the production of multimeric protein complexes, and related compositions
DE602004015980D1 (de) * 2003-06-17 2008-10-02 Sembiosys Genetics Inc Verfahren zur insulinproduktion in pflanzen
TW200526778A (en) * 2003-11-14 2005-08-16 Sembiosys Genetics Inc Methods for the production of apolipoproteins in transgenic plants
WO2005087249A1 (ja) * 2004-03-11 2005-09-22 Kurume University プロテアーゼ阻害剤及び疾患の予防又は治療剤
JP2006151861A (ja) * 2004-11-29 2006-06-15 Redox Bioscience Inc 喫煙によって引き起こされる臓器障害の予防乃至治療剤
GB0524884D0 (en) * 2005-12-06 2006-01-11 Syngenta Ltd Improvements in or relating to organic compounds
EP2573178A3 (en) 2007-07-10 2013-07-24 Monsanto Technology LLC Transgenic plants with enhanced agronomic traits
US20110081386A1 (en) * 2008-04-11 2011-04-07 Sembiosys Genetics, Inc. Controlled release of active agents from oleosomes
ES2384777B1 (es) * 2008-06-27 2013-06-19 Universidad Pública de Navarra Tiorredoxinas plastidiales: sobreexpresión y aplicaciones biotecnológicas.
ES2354537B1 (es) * 2008-06-27 2012-01-23 Universidad Pública de Navarra Tiorredoxinas plastidiales: sobreexpresión y aplicaciones biotecnológicas.
TWI377954B (en) * 2009-11-25 2012-12-01 Univ China Medical Oil body carriers, uses in target therapy and/or detection of the same, and fusion proteins comprised therein
CN102127562B (zh) * 2009-12-09 2013-01-30 安胜军 一种种子特异型表达载体及其构建方法与应用
CN103343137B (zh) * 2013-07-10 2015-05-20 吉林农业大学 一种含有表皮生长因子活性多肽的植物油体护肤乳液
CN103333915B (zh) * 2013-07-10 2015-08-05 吉林农业大学 一种含有碱性成纤维细胞生长因子活性多肽的植物油体护肤乳液
CN103343138B (zh) * 2013-07-10 2016-07-13 吉林农业大学 一种含有酸性成纤维细胞生长因子活性多肽的植物油体护肤乳液
KR101831888B1 (ko) * 2016-04-15 2018-04-16 (주)케어젠 항염증 활성을 갖는 펩타이드 및 이의 용도
CN106905435B (zh) * 2017-03-13 2020-04-10 武汉海沙百得生物技术有限公司 一种制备基于蛋白a突变体的结合蛋白的方法
WO2019014755A1 (en) * 2017-07-19 2019-01-24 Alcantara Research Group Inc. CHLOROPLASTS OF ALGAE ENRICHED IN RECOMBINANT POLYPEPTIDE, PROCESSES FOR PRODUCTION THEREOF AND USES THEREOF
JP6923166B2 (ja) * 2019-07-16 2021-08-18 住友ゴム工業株式会社 融合タンパク質、物質製造方法、ベクター、形質転換細胞、空気入りタイヤの製造方法及びゴム製品の製造方法
EP4060045A1 (en) * 2021-03-16 2022-09-21 Core Biogenesis A genetically engineered plant or part thereof adapted for the production of recombinant proteins and process thereof
AU2022296206A1 (en) * 2021-06-23 2024-01-04 Panasonic Intellectual Property Management Co., Ltd. Fusion protein, fusion protein production method, electrode, redox device, redox method, method for cutting disulfide bonds, and method for inactivating allergen
AU2022202825B1 (en) * 2022-04-28 2023-09-07 AUSTRALIAN HEALTH INDUSTRY Co. PTY LTD Polypeptide, polypeptide composition and application, and prepared anti-wrinkle lotion thereof

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151350A (en) * 1982-10-27 1992-09-29 Repligen Corporation Cloned genes encoding recombinant protein a
US4771036A (en) * 1986-02-10 1988-09-13 Trustees Of Columbia University In The City Of New York Method and ophthalmic composition for the prevention and reversal of cataracts
US4954618A (en) * 1986-02-14 1990-09-04 Genex Corporation Cloned streptococcal genes encoding protein G and their use to construct recombinant microorganisms to produce protein G
CA2044296A1 (en) * 1990-06-12 1991-12-13 Hiroaki Okamoto Oligonucleotide primers, and their application for high-fidelity detection of non-a, non-b hepatitis virus
US5650554A (en) * 1991-02-22 1997-07-22 Sembiosys Genetics Inc. Oil-body proteins as carriers of high-value peptides in plants
US6750046B2 (en) * 1991-02-22 2004-06-15 Sembiosys Genetics, Inc. Preparation of thioredoxin and thioredoxin reductase proteins on oil bodies
US5948682A (en) * 1991-02-22 1999-09-07 Sembiosys Genetics Inc. Preparation of heterologous proteins on oil bodies
US6288304B1 (en) * 1991-02-22 2001-09-11 Sembiosys Genetics Inc. Expression of somatotropin in plant seeds
US7091401B2 (en) * 1991-02-22 2006-08-15 Sembiosys Genetics Inc. Expression of epidermal growth factor in plant seeds
US5792506A (en) * 1991-10-12 1998-08-11 The Regents Of The University Of California Neutralization of food allergens by thioredoxin
AU678154B2 (en) * 1992-04-02 1997-05-22 Sembiosys Genetics Inc. Oil-body protein cis-elements as regulatory signals
SE9201331D0 (sv) * 1992-04-28 1992-04-28 Hightech Receptor C O Active Protein l och hybridproteiner daerav
US6046037A (en) * 1994-12-30 2000-04-04 Hiatt; Andrew C. Method for producing immunoglobulins containing protection proteins in plants and their use
JPH0912471A (ja) * 1995-06-29 1997-01-14 Noevir Co Ltd 皮膚外用剤
US5856452A (en) * 1996-12-16 1999-01-05 Sembiosys Genetics Inc. Oil bodies and associated proteins as affinity matrices
US6372234B1 (en) * 1997-05-27 2002-04-16 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6599513B2 (en) * 1997-05-27 2003-07-29 Sembiosys Genetics Inc. Products for topical applications comprising oil bodies
US6183762B1 (en) * 1997-05-27 2001-02-06 Sembiosys Genetics Inc. Oil body based personal care products
US7585645B2 (en) * 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
US6761914B2 (en) * 1997-05-27 2004-07-13 Sembiosys Genetics Inc. Immunogenic formulations comprising oil bodies
ES2301197T3 (es) * 1997-05-27 2008-06-16 Sembiosys Genetics Inc. Utilizaciones de cuerpos oleosos.
JP2000103743A (ja) * 1998-09-29 2000-04-11 Jiyunji Yodoi チオレドキシン活性を有するファミリーに属するポリペプチド類を含有する食品、化粧品及び医薬
US20060179514A1 (en) * 2001-07-05 2006-08-10 Sembiosys Genetics, Inc. Methods for the production of multimeric protein complexes, and related compositions
TW200526778A (en) * 2003-11-14 2005-08-16 Sembiosys Genetics Inc Methods for the production of apolipoproteins in transgenic plants

Also Published As

Publication number Publication date
AU3281902A (en) 2002-07-01
CN1486368A (zh) 2004-03-31
WO2002050289A9 (en) 2003-04-17
AU2002232819B2 (en) 2008-01-03
EA009181B1 (ru) 2007-12-28
WO2002050289A8 (en) 2005-01-20
WO2002050289A1 (en) 2002-06-27
MXPA03005548A (es) 2004-04-20
JP4570327B2 (ja) 2010-10-27
CA2432315A1 (en) 2002-06-27
IL156334A0 (en) 2004-01-04
BR0116220A (pt) 2003-09-23
EP1346056A1 (en) 2003-09-24
TWI317736B (en) 2009-12-01
CN100385005C (zh) 2008-04-30
NZ526822A (en) 2005-03-24
US20090197337A1 (en) 2009-08-06
KR20030066732A (ko) 2003-08-09
JP2004527227A (ja) 2004-09-09
AR037083A1 (es) 2004-10-20

Similar Documents

Publication Publication Date Title
EA200300708A1 (ru) Способы получения мультимерных белков и относящиеся к ним композиции
LTPA2016028I1 (lt) Imunoglobulino chimeriniai monomero-dimero hibridai
EA200001176A1 (ru) Гетероциклические ингибиторы p38
CY1105772T1 (el) Συνθεσεις και μεθοδοι για βελτιωμενη κυτταρικη καλλιεργεια
EA200300244A1 (ru) Антитела против двойного интегрина, композиции, способы и применение
ATE316982T1 (de) Mehrere zytokin-antikörper komplexen
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
EA200401591A1 (ru) Керамические аноды и способ их изготовления
EA200600686A1 (ru) Способы получения масляных тел, содержащих активные ингредиенты
EA200001200A1 (ru) Альгинатные гели с поддерживаемым высвобождением, подвергающиеся биологической деградации
DE69942459D1 (de) Isolierte nukleinsäuremoleküle die t-zellen induzierbare faktoren kodieren (tif), kodierte proteine und ihre anwendung
EA199801031A1 (ru) Ингибиторы протеинфарнезилтрансферазы
NO20043257D0 (no) Innkapslede bindingsproteiner som biosensorer
EA200201256A1 (ru) Способ переработки зерна и применяемые для этого трансгенные растения
ATE294229T1 (de) Verfahren zur trocknung von kompetenten zellen
EA199900381A1 (ru) Арил(тио)эфиры галогенпиримидина в качестве пестицидов
EA200201214A1 (ru) Замещенные тиоацетамиды
CY1110868T1 (el) Ελαχιστη αλληλουχια dna που δρα ως μονωτης της χρωματινης και η χρηση της στην πρωτεϊνικη εκφραση
EA200100012A1 (ru) Мостиковые инденопирролокарбазолы
EA200501250A1 (ru) Композиция, содержащая смесь активных начал, и способ ее получения
EA200501046A1 (ru) Эсциталопрамгидробромид и способ его получения
GB0010314D0 (en) Anti-freeze proteins their production and use
ATE284140T1 (de) Konservierung von zellen
EA200501244A1 (ru) Оксатиинкарбоксамиды
RU94043769A (ru) Способ повышения продукции протеина с, способ повышения уровня его модификации

Legal Events

Date Code Title Description
PC1A Registration of transfer to a eurasian application by force of assignment
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY RU